LITERATURE
原始候选快照
v3 复核前的候选池,完整保留,仅供查看,不会自动重新处理。 共 7004 篇。
| 论文 | 标识 | 日期 | 入排置信度 | 入排依据 | KM 状态 |
|---|---|---|---|---|---|
| Comparing adaptive and dose redistributed radiotherapy to conventional radiotherapy in head and neck cancer - Quality of life results from the phase III ARTFORCE trial.Radiother OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40651596无 PMCID | 2025-Sep | 0.95 | This is a quality-of-life analysis from a Phase III randomized trial in head and neck cancer. While it meets criteria for oncology, human, randomized, phase 3, and original result, it is excluded because the endpoint is patient-reported quality of life, not a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Additionally, the intervention is radiotherapy only (no drug-containing intervention). | 无 KM 图 |
| Clinical Trial: Association Between Early Disease Clearance and Long-Term Outcomes-4-Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis.Aliment Pharmacol Ther | PMID 40668079PMC12343057 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 已完成 |
| Individual-level analysis of the efficacy of albendazole and albendazole-ivermectin fixed-dose coformulation (FDC) against Trichuris trichiura and hookworms.Acta TropPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40669531无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Asian Patients With Moderate to Severe Psoriasis: Improvements in Patient-Reported Outcomes in a Randomized Trial.J Dermatol已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:AI 判定为 other。 | PMID 40671612PMC12411803 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Safety and Use of Eptacog Beta 225 µg/kg in Patients With Haemophilia A or B With Inhibitors.Haemophilia入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40674256PMC12462549 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.Diabetes Obes Metab入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40677091PMC12326891 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial.Lancet Respir MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40683298无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.Gynecol OncolAI 判定该论文不进入自动 KM 提取:The record explicitly states this is a Phase II study. | PMID 40700852PMC12398225 | 2025-Sep | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 无 KM 图 |
| Effect of olezarsen on lipoprotein-associated ApoC-III levels in patients with familial chylomicronemia syndrome.AtherosclerosisPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40706406无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effects of Vunakizumab Treatment on Detailed Dimensions of Patient-Reported Outcomes in Moderate-to-Severe Plaque Psoriasis Patients: A Post-Hoc Analysis of a Randomized Controlled Trial (NCT04839016).Clin TherPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40713422无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial.Ann Intern MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40720835无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-Term Safety and Efficacy of Risankizumab to Treat Moderate-to-Severe Plaque Psoriasis: Final LIMMitless Phase 3, Open-Label Extension Trial Results.Am J Clin Dermatol入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40728772PMC12436474 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.Neurol Neuroimmunol Neuroinflamm入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40743487PMC12316463 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| PERCEIVE: A retrospective, qualitative interview-based study of the impact of vasomotor symptoms associated with menopause on the lives of individuals who are not suitable candidates for hormone therapy.Maturitas入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40752049无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Treatment With Canagliflozin Versus Placebo in Children and Adolescents With Type 2 Diabetes : A Randomized Clinical Trial.Ann Intern MedPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40759025无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial.Lung Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40774040无 PMCID | 2025-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 无 KM 图 |
| Theta burst stimulation of temporo-parietal cortex regions for the treatment of persistent auditory hallucinations: a multicentre, randomised, sham-controlled, triple-blind phase 3 trial in Germany.Lancet PsychiatryPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40774272无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.Nat Med疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40775055无 PMCID | 2025-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Herpes zoster recurrence, and safety and immunogenicity of the recombinant zoster vaccine in adults aged ≥50 years with a history of herpes zoster: A phase 3, randomized controlled trial.J InfectPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40780591无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effects of Prenatal DHA Dose on Infant Visual Attention.Dev Psychobiol已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:CONSORT/入组流程图;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。 | PMID 40791013PMC13182510 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Health-related quality of life in patients with KRASG12C-mutated chemorefractory metastatic colorectal cancer treated with sotorasib plus panitumumab or standard of care (CodeBreaK 300): results from a phase 3, randomised clinical trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40812325无 PMCID | 2025-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.Lancet NeurolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40818473无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Modified Atkins diet versus topiramate in young children with epileptic spasms refractory to steroids and vigabatrin: a randomised open-label trial.SeizurePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40840039无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Endovascular Therapy Versus Medical Management for Large Ischemic Infarct: 1-Year Outcomes of the ANGEL-ASPECT Trial.StrokePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40854041无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| First-line benmelstobart plus anlotinib versus sunitinib in advanced renal cell carcinoma (ETER100): a multicentre, randomised, open-label, phase 3 trial.Lancet Oncol疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40907513无 PMCID | 2025-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| De-escalated adjuvant radiotherapy versus standard adjuvant treatment for human papillomavirus-associated oropharyngeal squamous cell carcinoma (MC1675): a phase 3, open-label, randomised controlled trial.Lancet OncolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40907518无 PMCID | 2025-Sep | 0.45 | The trial is a phase 3, randomized, drug-interventional oncology study with original results, but the primary endpoint is cumulative toxicity, not a time-to-event efficacy endpoint. No OS/PFS/DFS/EFS/RFS/TTP, Kaplan-Meier, or HR data is reported. | 无 KM 图 |
| Reduction in Dressing Change Burden in Patients With Epidermolysis Bullosa-Impact of Oleogel-S10.J Dermatol已检查 3 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:森林图/亚组分析图;FIGURE 2:森林图/亚组分析图;FIGURE 3:森林图/亚组分析图。 | PMID 40908727PMC12411827 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of best response to ibrutinib plus Bendamustine and rituximab on PFS in MCL: a secondary analysis of SHINE.Ann Hematol | PMID 40940567PMC12552230 | 2025-Sep | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Donanemab in preclinical Alzheimer's disease: Screening and baseline data from TRAILBLAZER-ALZ 3.Alzheimers Dement疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other;FIGURE 3:森林图/亚组分析图;FIGURE 4:森林图/亚组分析图。 | PMID 40955720PMC12439032 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Belantamab Mafodotin with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Comprehensive Exposure-Response Analysis of the DREAMM-8 Study.Target Oncol | PMID 40958065PMC12454471 | 2025-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| A Randomised Controlled Trial on the Treatment of Recurrent Implantation Failure Women Who Failed Egg Donation Cycles Using Low-Dose GM-CSF.Am J Reprod ImmunolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40965804无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Effect of Cardioprotection on the Right Ventricular Function in Breast Cancer Patients Receiving Potentially Cardiotoxic Therapy: A SAFE Trial Substudy.Echocardiography已检查 5 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other;FIGURE 5:森林图/亚组分析图。 | PMID 40965835PMC12445402 | 2025-Sep | 0.85 | Although the record describes a substudy of a definitive randomized oncology trial in humans, the reported outcomes are cardiac toxicity endpoints (RV function, CTRCD), not the required survival or efficacy outcomes for Kaplan-Meier digitization. | 无 KM 图 |
| Aesthetic Improvements Over Time: Long-Term Efficacy and Additional Outcomes of IncobotulinumtoxinA in the Simultaneous Treatment of Upper Facial Lines.J Cosmet Dermatol已检查 4 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 other;FIGURE 2:AI 判定为 other;FIGURE 3:AI 判定为 other;FIGURE 4:AI 判定为 other。 | PMID 40968493PMC12446747 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Multimodal prognostic modeling of individual cognitive trajectories to enhance trial efficiency in preclinical Alzheimer's disease.Alzheimers Dement入排复审未纳入:未发现恶性肿瘤人群证据。 | PMID 40990131PMC12457986 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab.JCO Precis Oncol已检查 2 张 PubMed Figure,均未识别为 KM 图:FIG 1.:AI 判定为 flow diagram;FIG 2.:AI 判定为 other。 | PMID 40991883PMC12487655 | 2025-Sep | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Atogepant for the preventive treatment of episodic migraine in Japanese participants: A phase 2/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE).CephalalgiaPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41002192无 PMCID | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib.Ann HematolPubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 41071292PMC12552232 | 2025-Sep | 0.90 | The record describes a health-related quality-of-life (HRQoL) analysis from a Phase III randomized trial. While it is oncology, human, randomized, Phase III, has a drug intervention, and is an original result, its primary analysis and endpoint are not time-to-event efficacy. The abstract focuses on HRQoL outcomes and clinical response as predictors, not on a primary or key secondary time-to-event endpoint like OS, PFS, DFS, EFS, RFS, TTP, or survival analyses with Kaplan-Meier or hazard ratios. Therefore, it is excluded per the criteria requiring a time-to-event efficacy endpoint. | 无 KM 图 |
| Dihydroartemisinin-piperaquine plus sulfadoxine-pyrimethamine versus either drug alone for intermittent preventive treatment of malaria in pregnancy: A double-blind, randomized, controlled phase 3 trial from Uganda.PLoS Med已检查 3 张 PubMed Figure,均未识别为 KM 图:Fig 1:AI 判定为 flow diagram;Fig 2:森林图/亚组分析图;Fig 3:森林图/亚组分析图。 | PMID 40966190PMC12445490 | 2025-Sep | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Weight-independent amelioration of adipokine profile by enavogliflozin, a selective SGLT2 inhibitor, in patients with type 2 diabetes.Cardiovasc Diabetol已检查 1 张 PubMed Figure,均未识别为 KM 图:Fig. 1:AI 判定为 other。 | PMID 40887579PMC12400600 | 2025-Aug-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Etrasimod for the symptomatic relief of ulcerative colitis: a post-hoc analysis from the ELEVATE UC clinical programme.BMJ Open Gastroenterol已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:AI 判定为 multi panel km;Figure 2:AI 判定为 multi panel km;Figure 3:AI 判定为 other。 | PMID 40889900PMC12406896 | 2025-Aug-31 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Long-term efficacy and immune response of CoronaVac in Brazilian health care workers: Insights from PROFISCOV unblinded trial.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40714527无 PMCID | 2025-Aug-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40714528无 PMCID | 2025-Aug-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Immunogenicity and safety of quadrivalent recombinant influenza vaccine in Korean adults: Phase III, randomized study.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40752250无 PMCID | 2025-Aug-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| A phase 3 randomized trial (STRIDE-9) to evaluate the safety, tolerability, and immunogenicity of V116, a population-specific pneumococcal conjugate vaccine, in pneumococcal vaccine-naïve Japanese adults ≥65 years of age.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40763490无 PMCID | 2025-Aug-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| The impact of pneumococcal vaccination and nasopharyngeal colonization on the performance of a serotype-specific urine antigen detection (SSUAD) assay.VaccinePubMed 未展示 Figure,且无可用 PMC 全文;如需图片,需要从出版社页面获取。 | PMID 40886427无 PMCID | 2025-Aug-30 | 0.98 | 未发现恶性肿瘤人群证据。 | 无 KM 图 |
| Adjuvant icotinib for resected EGFR-mutated stage II-IIIA non-small-cell lung cancer (ICTAN, GASTO1002): a randomized comparison study.Signal Transduct Target Ther | PMID 40866342PMC12391381 | 2025-Aug-28 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 已完成 |
| Baseline tumor burden predicts the efficacy of first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer: results from 2 phase 3 randomized placebo-controlled trials.BMC Cancer | PMID 40866864PMC12382186 | 2025-Aug-27 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 已完成 |
| Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.Blood Adv已检查 2 张 PubMed Figure,均未识别为 KM 图:captionless-figure:AI 判定为 other;Figure 1:森林图/亚组分析图。 | PMID 40334070PMC12359220 | 2025-Aug-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |
| Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL.Blood Adv | PMID 40334072PMC12391778 | 2025-Aug-26 | 0.45 | The study is an oncology, human, randomized, Phase III trial with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint. The primary endpoint is major molecular response (MMR) at week 156, a categorical response rate, not a time-to-event outcome. Therefore, it does not meet the eligibility criteria for inclusion in the KM digitization cohort. | 已完成 |
| A140 plus mFOLFOX6 compared with cetuximab plus mFOLFOX6 for first-line RAS wild-type metastatic colorectal cancer: A randomized clinical trial.Eur J Cancer疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。 | PMID 40737898无 PMCID | 2025-Aug-26 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 无 KM 图 |